{
    "nct_id": "NCT06045689",
    "official_title": "A Phase 3b, Open-label Study Evaluating the Efficacy and Safety of Luspatercept (BMS-986346/ACE-536) Initiated at Maximum Approved Dose in LR-MDS With IPSS-R Very Low-, Low-, or Intermediate-risk Who Require RBC Transfusions (MAXILUS)",
    "inclusion_criteria": "* Participant had documented diagnosis of MDS according to World Health Organization (WHO) classification that met Revised International Prognostic Scoring System (IPSS-R) classification of very low-, low-, or intermediate-risk disease.\n* Participant has an Eastern Cooperative Oncology Group (ECOG) score of 0, 1, or 2.\n* Participant must have red blood cell transfusions according to study criteria.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Participant has known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or gastrointestinal bleeding.\n* Participant has had a prior allogeneic or autologous stem cell transplant.\n* Participant has known history or diagnosis of AML.\n* Participant has uncontrolled hypertension.\n\nOther protocol-defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}